ClinicalTrials.gg
CompletedNCT01958671Updated Sep 29, 2017Results posted

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
9th of 28
461 · median 83
Started
2013
with 5 others
Phase 3
11 of 28
none open now
Registered
8th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise. This trial consists of a run-in period of 3 to 11 weeks, a 26-week placebo-controlled treatment period (Phase A), and a 26-week active treatment period (Phase B). The primary hypotheses of the trial are that at Week 26, the mean reduction from baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is greater than that for placebo and the mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that for placebo.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of T2DM in accordance to American Diabetes Association guidelines
  • Participants with no prior allowable oral anti-hyperglycemic agents (AHA) for at least 8 weeks prior to study participation or participants on a single allowable oral AHA at the start of study participation
  • Participants on a single allowable AHA must be willing to discontinue this medication at the Screening Visit (S2) and remain off this medication for the duration of the trial. Allowable oral AHAs for discontinuation are metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides or alpha-glucosidase inhibitors.

Exclusion criteria

Exclusion Criteria:

  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study participation
  • A abnormality
  • A history of ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer
  • A known or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor or metformin
  • On a blood pressure or lipid altering medication that have not been on a stable dose for at least 4 weeks prior to study participation
  • A surgical procedure within 4 weeks prior to study participation or planned major surgery during the trial
  • Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial
  • Pregnant or breast-feeding, or is expecting to conceive during the trial, including 14 days following the last dose of study drug
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg/Ertugliflozin 5 mg

    Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.

    Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Placebo to Metformin · Drug: Glimepiride

  • Experimental
    Ertugliflozin 15 mg/Ertugliflozin 15 mg

    Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.

    Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Metformin · Drug: Placebo to Metformin · Drug: Glimepiride

  • Other
    Placebo/Metformin

    Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.

    Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Glimepiride

Interventions

  • One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

    Also known as: MK-8835, PF-04971729

  • One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

    Also known as: MK-8835, PF-04971729

  • DrugPlacebo to Ertugliflozin

    One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).

  • 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.

    Also known as: Glucophage XR, Carbophage SR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, Diaformin, Siofor and Metfogamma.

  • DrugPlacebo to Metformin

    1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.

  • Dosing and titration of glimepiride as rescue therapy was determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Change From Baseline In A1C at Week 26

    A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Experiencing An Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

    Time frame: Up to 54 weeks (including 2 weeks following last dose)

  3. Percentage of Participants Discontinuing Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change From Baseline in FPG at Week 26

    The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Body Weight at Week 26

    The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  3. Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26

    A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Week 26

  4. Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level

    Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.

    Time frame: Baseline

  5. Change From Baseline in 2-hr PPG at Week 26

    The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  6. Baseline Sitting Systolic Blood Pressure (SBP)

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.

    Time frame: Baseline

  7. Change From Baseline in SBP at Week 26

    The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

  8. Baseline Sitting Diastolic Blood Pressure (DBP)

    Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.

    Time frame: Baseline

  9. Change From Baseline in DBP at Week 26

    The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.

    Time frame: Baseline and Week 26

07

Results

Posted Sep 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneErtugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/Metformin
Started156152153
Completed137128121
Not completed192432
Withdrew: Adverse event115
Withdrew: Death100
Withdrew: Excluded medication001
Withdrew: Hyperglycemia002
Withdrew: Lost to follow-up7117
Withdrew: Non-compliance with study drug111
Withdrew: Pregnancy001
Withdrew: Protocol violation010
Withdrew: Study site terminated by sponsor101
Withdrew: Participant moved001
Withdrew: Withdrawal by subject81013

Outcome measures

PrimaryChange From Baseline In A1C at Week 26

A1C is measured as percent. The change from baseline is the Week 26 A1C percent minus the Week 0 A1C percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percent
Change From Baseline In A1C at Week 26
PercentErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline In A1C at Week 26-0.79 (-0.95 to -0.63)-0.96 (-1.12 to -0.80)0.20 (0.02 to 0.37)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -0.99 · 95% CI -1.22 to -0.76Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -1.16 · 95% CI -1.39 to -0.93Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
PrimaryPercentage of Participants Experiencing An Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

Time frame:
Up to 54 weeks (including 2 weeks following last dose)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing An Adverse Event (AE)
Percentage of participantsErtugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/Metformin
Percentage of Participants Experiencing An Adverse Event (AE)64.162.566.7
Statistical analysis
  • Ertugliflozin 5 mg/Ertugliflozin 5 mg vs Placebo/Metformin · Difference in percentage: -2.6 · 95% CI -13.1 to 8.1Based on Miettinen \& Nurminen method.
  • Ertugliflozin 15 mg/Ertugliflozin 15 mg vs Placebo/Metformin · Difference in percentage: -4.2 · 95% CI -14.8 to 6.6Based on Miettinen \& Nurminen method.
PrimaryPercentage of Participants Discontinuing Study Treatment Due to an AE

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Data presented include data following the initiation of rescue therapy.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing Study Treatment Due to an AE
Percentage of participantsErtugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/Metformin
Percentage of Participants Discontinuing Study Treatment Due to an AE4.53.96.5
Statistical analysis
  • Ertugliflozin 5 mg/Ertugliflozin 5 mg vs Placebo/Metformin · Difference in percentage: -2.0 · 95% CI -7.7 to 3.3Based on Miettinen \& Nurminen method.
  • Ertugliflozin 15 mg/Ertugliflozin 15 mg vs Placebo/Metformin · Difference in percentage: -2.6 · 95% CI -8.2 to 2.7Based on Miettinen \& Nurminen method.
SecondaryChange From Baseline in FPG at Week 26

The change from baseline is the Week 26 FPG minus the Week 0 FPG. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of glycemic rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG at Week 26
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in FPG at Week 26-33.96 (-39.85 to -28.06)-43.44 (-49.39 to -37.49)0.57 (-6.02 to 7.16)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -34.53 · 95% CI -42.76 to -26.29Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -44.01 · 95% CI -52.28 to -35.74Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
SecondaryChange From Baseline in Body Weight at Week 26

The change from baseline is the Week 26 body weight minus the Week 0 body weight. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in Body Weight at Week 26-3.18 (-3.72 to -2.63)-3.58 (-4.13 to -3.02)-1.42 (-2.02 to -0.81)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -1.76 · 95% CI -2.57 to -0.95Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -2.16 · 95% CI -2.98 to -1.34Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
SecondaryPercentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26

A1C is measured as percent. Laboratory measurements were performed after an overnight fast ≥10 hours in duration. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 26
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Percentage of Participants With A1C <7% (<53 mmol/Mol) at Week 2628.235.813.1
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.59 · 95% CI 1.85 to 6.95Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline eGFR.
  • Ertugliflozin 15 mg vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.77 · 95% CI 3.46 to 13.24Fixed effects for treatment, prior antihyperglycemic medication, covariates for baseline A1C and baseline
SecondaryBaseline 2-hour Post-prandial Glucose (2-hr PPG) Level

Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the Mixed Meal Tolerance Test (MMTT). Change from baseline in 2-hr PPG level at Week 26 data are presented in the following outcome measure.

Time frame:
Baseline
Reported as:
Mean · mg/dL
Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline 2-hour Post-prandial Glucose (2-hr PPG) Level260.32 ± 76.110262.91 ± 78.189256.21 ± 76.917
SecondaryChange From Baseline in 2-hr PPG at Week 26

The change from baseline is the Week 26 2-hr PPG minus the Week 0 2-hr PPG. Laboratory measurements were performed 120 minutes following the start of the administration of the meal for the MMTT. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hr PPG at Week 26
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in 2-hr PPG at Week 26-64.15 (-74.34 to -53.96)-62.45 (-72.91 to -51.98)4.88 (-6.15 to 15.92)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -69.03 · 95% CI -83.24 to -54.83Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = <0.001 · Difference in least squares means: -67.33 · 95% CI -81.73 to -52.93Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
SecondaryBaseline Sitting Systolic Blood Pressure (SBP)

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in SBP at Week 26 data are presented in the following outcome measure.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Sitting Systolic Blood Pressure (SBP)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline Sitting Systolic Blood Pressure (SBP)130.49 ± 13.511129.67 ± 14.208129.80 ± 14.464
SecondaryChange From Baseline in SBP at Week 26

The change from baseline is the Week 26 SBP minus the Week 0 SBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP at Week 26
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in SBP at Week 26-5.54 (-7.32 to -3.76)-3.93 (-5.74 to -2.12)-2.22 (-4.30 to -0.14)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.015 (Nominal p-value) · Difference in least squares means: -3.31 · 95% CI -5.98 to -0.65Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.213 · Difference in least squares means: -1.71 · 95% CI -4.40 to 0.98Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
SecondaryBaseline Sitting Diastolic Blood Pressure (DBP)

Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Change from baseline in DBP at Week 26 data are presented in the following outcome measure.

Time frame:
Baseline
Reported as:
Mean · mmHg
Baseline Sitting Diastolic Blood Pressure (DBP)
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Baseline Sitting Diastolic Blood Pressure (DBP)78.46 ± 8.11778.53 ± 7.71478.13 ± 7.458
SecondaryChange From Baseline in DBP at Week 26

The change from baseline is the Week 26 DBP minus the Week 0 DBP. Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. Data presented exclude data following the initiation of rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP at Week 26
mmHgErtugliflozin 5 mgErtugliflozin 15 mgPlacebo
Change From Baseline in DBP at Week 26-2.52 (-3.65 to -1.40)-1.10 (-2.24 to 0.05)-0.72 (-2.05 to 0.60)
Statistical analysis
  • Ertugliflozin 5 mg vs Placebo · Constrained longitudinal data analysis · p = 0.039 (Nominal p-value) · Odds ratio (or): -1.80 · 95% CI -3.51 to -0.09Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.
  • Ertugliflozin 15 mg vs Placebo · Constrained longitudinal data analysis · p = 0.669 (Nominal p-value) · Difference in least squares means: -0.37 · 95% CI -2.09 to 1.35Fixed effects for treatment, time, prior anti-hyperglycemic medication, baseline eGFR and the interaction of time by treatment.

Adverse events

Collected over Up to 54 weeks (+/- 3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg/Ertugliflozin 5 mg—11/156 (7.1%)50/156 (32.1%)
Ertugliflozin 15 mg/Ertugliflozin 15 mg—6/152 (3.9%)48/152 (31.6%)
Placebo/Metformin—8/153 (5.2%)68/153 (44.4%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventErtugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/Metformin
LabyrinthitisInfections and infestations0/1561/1520/153
Periorbital abscessInfections and infestations0/1561/1520/153
Periorbital cellulitisInfections and infestations0/1561/1520/153
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1561/1520/153
Hepatic cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1561/1520/153
Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1561/1520/153
Squamous cell carcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1561/1520/153
EpistaxisRespiratory, thoracic and mediastinal disorders0/1561/1520/153
HaemoptysisRespiratory, thoracic and mediastinal disorders0/1561/1520/153
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1561/1520/153
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/Metformin
DiarrhoeaGastrointestinal disorders8/1565/15223/153
Urinary tract infectionInfections and infestations13/15610/15219/153
NauseaGastrointestinal disorders4/1563/15212/153
Vulvovaginal mycotic infectionInfections and infestations12/1568/1522/153
NasopharyngitisInfections and infestations8/15611/1526/153
ConstipationGastrointestinal disorders11/1562/1524/153
Upper respiratory tract infectionInfections and infestations9/15610/1529/153
HypoglycaemiaMetabolism and nutrition disorders2/1566/15210/153
HeadacheNervous system disorders6/1567/1529/153
BronchitisInfections and infestations5/1561/1528/153

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Mean56.8 ± 11.456.2 ± 10.856.1 ± 10.956.4 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Female676271200
Male899082261
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Mean8.16 ± 0.888.35 ± 1.128.11 ± 0.928.21 ± 0.98
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mg/dL)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Mean180.9 ± 48.5179.1 ± 48.2180.2 ± 45.8180.1 ± 47.4
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(mL/min/1.75m^2)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Mean88.5 ± 18.488.3 ± 18.086.2 ± 19.487.7 ± 18.6
Body weight
Body weight(Kilograms)Ertugliflozin 5 mg/Ertugliflozin 5 mgErtugliflozin 15 mg/Ertugliflozin 15 mgPlacebo/MetforminTotal
Mean94.0 ± 25.490.6 ± 18.394.2 ± 25.292.9 ± 23.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017 May;19(5):721-728. doi: 10.1111/dom.12888. Epub 2017 Feb 22. PubMed 28116776 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27. PubMed 32700393 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗
  • Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7. PubMed 31064361 ↗
  • Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018 Jun;20(6):1453-1460. doi: 10.1111/dom.13251. Epub 2018 Feb 23. PubMed 29419917 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jul 2016, 33 months.

Results were first posted in Sep 2017, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 33 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2013
First posted
Oct 9, 2013
StartActual
Oct 9, 2013
Primary completionActual
Jul 28, 2016
CompletionActual
Jul 28, 2016
Results first posted
Sep 29, 2017
Last update
Sep 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01958671
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Oct 9, 2013
Primary completion
Jul 28, 2016
Completion
Jul 28, 2016
Results posted
Sep 29, 2017
Last update
Sep 29, 2017

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion